Hansoh Acquires China Rights to Osteoarthritis Therapy in Deal Worth $63 Million-Plus
publication date: Sep 27, 2022
Shanghai Hansoh Pharma acquired Greater China rights to an injection for osteoarthritis of the knee from Belgium’s KiOmed Pharma. KiOmedinevsOne is a novel highly purified polysaccharide based on a mushroom that is administered by injection. Unlike hyaluronic acid, the therapy has a dual mechanism that reduces oxidative stress and increases lubrication of the joint. Hansoh will make an unspecified upfront payment and be responsible for up to $63 million in milestones, plus royalties on sales. KiOmedinevsOne, an animal-free product, was approved for EU use last year. More details....
Stock Symbol: (HK: 3692)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.